IL33 and gastric cancer: Interestingly, in GC patients, the transcriptional signature of activated MCs with IL-33 and TAMs’ markers correlates with decreased patient survival, suggesting that IL-33 is a potent tumor-derived molecule capable of activating MCs to foster their pro-tumorigenic role in GC [61].